Cardunolizumab - Akeso Biopharma/Innovent Biologics
Latest Information Update: 22 Mar 2024
At a glance
- Originator Akeso Biopharma; Innovent Biologics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Vulvovaginal cancer
Most Recent Events
- 12 Mar 2024 Preclinical trials in Vulvovaginal cancer in China (Parenteral)
- 12 Mar 2024 Zhejiang Cancer Hospital in collaboration with Akeso Biopharma and Innovent Biologics plan a phase II trial in Vulvovaginal cancer (Combination therapy, Metastatic disease, Recurrent) in China in March 2024 (NCT06292689)